Corvus 制药

最新新闻

• 评级变动
  Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $28
  \u5e02\u573a\u8d44\u8baf · 2026/1/21
• 评级变动
  H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $27
  \u5e02\u573a\u8d44\u8baf · 2026/1/21
• 评级变动
  Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/3/13
• 评级变动
  Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $32
  \u5e02\u573a\u8d44\u8baf · 2026/1/21
• 评级变动
  Jefferies Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2026/1/23
• 评级变动
  Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2025/12/10
• 评级变动
  Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/1/21
• Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2025/10/29
• 评级变动
  Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/1/29
• 评级变动
  H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2025/11/5
• 评级变动
  Goldman Sachs Initiates Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/4/17
• 评级变动
  Goldman Sachs Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Cuts Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2025/8/8
• H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $27 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• Corvus Pharmaceuticals (CRVS.US) will release its earnings report after market close on August 6.
  \u5e02\u573a\u8d44\u8baf · 2026/8/1
• 评级变动
  Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2025/11/5

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。